These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 16102106)

  • 1. Stromelysin-1 promoter 5A/6A polymorphism is an independent genetic prognostic risk factor and interacts with smoking cessation after index premature myocardial infarction.
    Liu PY; Li YH; Tsai WC; Tsai LM; Chao TH; Wu HL; Chen JH
    J Thromb Haemost; 2005 Sep; 3(9):1998-2005. PubMed ID: 16102106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic effect of stromelysin-1 (matrix metallo-proteinase-3) promoter 5A/6A polymorphism with smoking on the onset of young acute myocardial infarction.
    Liu PY; Chen JH; Li YH; Wu HL; Shi GY
    Thromb Haemost; 2003 Jul; 90(1):132-9. PubMed ID: 12876636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction between smoking and the stromelysin-1 (MMP3) gene 5A/6A promoter polymorphism and risk of coronary heart disease in healthy men.
    Humphries SE; Martin S; Cooper J; Miller G
    Ann Hum Genet; 2002 Nov; 66(Pt 5-6):343-52. PubMed ID: 12485468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction.
    Terashima M; Akita H; Kanazawa K; Inoue N; Yamada S; Ito K; Matsuda Y; Takai E; Iwai C; Kurogane H; Yoshida Y; Yokoyama M
    Circulation; 1999 Jun; 99(21):2717-9. PubMed ID: 10351963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction.
    Beyzade S; Zhang S; Wong YK; Day IN; Eriksson P; Ye S
    J Am Coll Cardiol; 2003 Jun; 41(12):2130-7. PubMed ID: 12821236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The stromelysin-1 5A/6A promoter polymorphism is a disease marker for the extent of coronary heart disease.
    Schwarz A; Haberbosch W; Tillmanns H; Gardemann A
    Dis Markers; 2002; 18(3):121-8. PubMed ID: 12515907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic variation in human stromelysin gene promoter and common carotid geometry in healthy male subjects.
    Gnasso A; Motti C; Irace C; Carallo C; Liberatoscioli L; Bernardini S; Massoud R; Mattioli PL; Federici G; Cortese C
    Arterioscler Thromb Vasc Biol; 2000 Jun; 20(6):1600-5. PubMed ID: 10845878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute myocardial infarction in young adults: prognostic role of angiotensin-converting enzyme, angiotensin II type I receptor, apolipoprotein E, endothelial constitutive nitric oxide synthase, and glycoprotein IIIa genetic polymorphisms at medium-term follow-up.
    Brscic E; Bergerone S; Gagnor A; Colajanni E; Matullo G; Scaglione L; Cassader M; Gaschino G; Di Leo M; Brusca A; Pagano GF; Piazza A; Trevi GP
    Am Heart J; 2000 Jun; 139(6):979-84. PubMed ID: 10827377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotype-phenotype association of matrix metalloproteinase-3 polymorphism and its synergistic effect with smoking on the occurrence of acute coronary syndrome.
    Liu PY; Li YH; Chan SH; Lin LJ; Wu HL; Shi GY; Chen JH
    Am J Cardiol; 2006 Oct; 98(8):1012-7. PubMed ID: 17027562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haplotype analysis of the matrix metalloproteinase 3 gene and myocardial infarction in a Chinese Han population. The Beijing atherosclerosis study.
    Zhou X; Huang J; Chen J; Su S; Chen R; Gu D
    Thromb Haemost; 2004 Oct; 92(4):867-73. PubMed ID: 15467919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix Metalloproteinase 3 Gene Polymorphism and Its Level Predict Morbidity After Acute Myocardial Infarction.
    Abd El-Aziz TA; Mohamed RH
    Am J Clin Pathol; 2016 Jan; 145(1):134-9. PubMed ID: 26712881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic variations of matrix metalloproteinase-1 and -3 promoter regions and their associations with susceptibility to myocardial infarction in Japanese.
    Nojiri T; Morita H; Imai Y; Maemura K; Ohno M; Ogasawara K; Aizawa T; Saito A; Hayashi D; Hirata Y; Sugiyama T; Yamazaki T; Nagai R
    Int J Cardiol; 2003 Dec; 92(2-3):181-6. PubMed ID: 14659851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The roles of stromelysin-1 and the gelatinase B gene polymorphism in stable angina.
    Kim JS; Park HY; Kwon JH; Im EK; Choi DH; Jang YS; Cho SY
    Yonsei Med J; 2002 Aug; 43(4):473-81. PubMed ID: 12205736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes.
    Yamada Y; Izawa H; Ichihara S; Takatsu F; Ishihara H; Hirayama H; Sone T; Tanaka M; Yokota M
    N Engl J Med; 2002 Dec; 347(24):1916-23. PubMed ID: 12477941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stromelysin-1 (MMP-3) gene 5A/6A promoter polymorphism is associated with blood pressure in a community population.
    Beilby JP; Chapman CM; Palmer LJ; McQuillan BM; Thompson PL; Hung J
    J Hypertens; 2005 Mar; 23(3):537-42. PubMed ID: 15716694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5A/6A polymorphism of the stromelysin-1 gene and angiographic restenosis after coronary artery stenting.
    Chiou KR; Chung SL; Charng MJ
    J Chin Med Assoc; 2005 Nov; 68(11):506-12. PubMed ID: 16323393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 5A Allele of the MMP3-Gene Promoter Polymorphism Is a Risk Factor for Poor Outcome of Hemodialysis Patients.
    Dragovic JT; Popovic J; Djuric P; Bulatovic A; Jankovic A; Buzadzic I; Dimkovic N
    Tohoku J Exp Med; 2017 Aug; 242(4):273-279. PubMed ID: 28781337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic effect of stromelysin-1 (matrix metalloproteinase-3) promoter (-1171 5A->6A) polymorphism in oral submucous fibrosis and head and neck lesions.
    Chaudhary AK; Singh M; Bharti AC; Singh M; Shukla S; Singh AK; Mehrotra R
    BMC Cancer; 2010 Jul; 10():369. PubMed ID: 20630073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetic effect of the stromelysin (MMP3) polymorphism on stroke risk in relation to antihypertensive treatment: the genetics of hypertension associated treatment study.
    Sherva R; Ford CE; Eckfeldt JH; Davis BR; Boerwinkle E; Arnett DK
    Stroke; 2011 Feb; 42(2):330-5. PubMed ID: 21183746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum matrix metalloproteinase-3 concentration is influenced by MMP-3 -1612 5A/6A promoter genotype and associated with myocardial infarction.
    Samnegård A; Silveira A; Lundman P; Boquist S; Odeberg J; Hulthe J; McPheat W; Tornvall P; Bergstrand L; Ericsson CG; Hamsten A; Eriksson P
    J Intern Med; 2005 Nov; 258(5):411-9. PubMed ID: 16238676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.